Elsevier

Neuroscience

Volume 415, 1 September 2019, Pages 184-200
Neuroscience

RESEARCH ARTICLE
Genotype and Injury Effect on the Expression of a Novel Hypothalamic Protein Sushi Repeat-Containing Protein X-Linked 2 (SRPX2)

https://doi.org/10.1016/j.neuroscience.2019.07.040Get rights and content

Highlights

  • Genetic deficiency of uPAR and uPA did not change the expression of SRPX2 protein in the hypothalamus.

  • CCI-induced acquired brain injury did not regulate SRPX2 gene or protein expression in the hypothalamus.

  • Genetic deficiency of uPA resulted in acute post-CCI upregulation of Srpx2 gene expression in the perilesional cortex.

  • SRPX2 expression in hypothalamus is resistant to genetic deficiencies in the urokinase-system and acquired brain injury.

  • Elevated Srpx2 gene expression in perilesional cortex can contribute to post-TBI recovery process.

Abstract

Sushi repeat-containing protein X-linked 2 (SRPX2) is a novel hypothalamic protein and a ligand of the urokinase-type plasminogen activator receptor (uPAR), which is essential for proteolysis of extracellular matrix and tissue remodeling after an insult to the brain. However, little is known about regulation of SRPX2. Our objective was to investigate if SRPX2 expression is altered by (i) the deficiency of uPAR or uPA (urokinase-type plasminogen activator), and (ii) traumatic brain injury (TBI). SRPX2 expression was assessed in wild type (Wt), Plaur−/− (uPAR-deficient), and Plau−/− (uPA-deficient) mice, with and without controlled cortical impact injury (CCI). The number of SRPX2 + neurons in hypothalamus was comparable to that in Wt littermates in Plaur−/− (2985 ± 138 vs. 2890 ± 92, p > 0.05) and Plau−/− mice (2180 ± 232 vs. 2027 ± 77, p > 0.05). The number of hypothalamic SRPX2 + neurons in the Wt-CCI group was comparable to that in controls (3645 ± 288 vs. 3385 ± 192, p > 0.05). Hypothalamic, hippocampal and thalamic Srpx2 gene expression was unaltered after TBI. However, at 4 days post-TBI Srpx2 gene expression was upregulated in the perilesional cortex of Plau−/−-CCI mice up to 123% of that in the sham group (p < 0.05). Unsupervised hierarchical clustering using SRPX2 expression did not identify genotype or injury-specific clusters. Our data demonstrate that SRPX2 expression in the hypothalamus is resistant to genetic deficiencies in the urokinase-system or to the hypothalamus-affecting TBI. The contribution of elevated Srpx2 gene expression in perilesional cortex to post-TBI recovery process, however, requires further exploration.

Introduction

According to an estimate, each year 69 million individuals suffer traumatic brain injury (TBI) worldwide (Dewan et al., 2018). TBI leads to tissue damage through cerebral contusion, hemorrhage, altered metabolism and differential gene expression, underlying the evolution of neurologic and psychiatric co-morbidities (Maas et al., 2008). Furthermore, TBI accounts for 15–20% of acquired epilepsy and 5% of all epilepsies (Herman, 2002), leading to development of chronic co-morbidities, resulting in increased disease and economic burden (Pitkänen et al., 2014a). The lack of pharmacotherapies available to improve the post-TBI outcome is a major unmet medical need. Recent data indicate that post-injury remodeling of the extracellular matrix (ECM) is critical for fostering the tissue recovery and alleviation of evolution of co-morbidities, and is thus a potentially rich source for identification of novel treatment targets (Soleman et al., 2013, Pitkänen et al., 2014b).

Urokinase-type plasminogen activator receptor (uPAR) is an essential component of the ECM fibrinolytic system (Sumi et al., 1992, Preissner et al., 2000, Semina et al., 2016). Together with other components of “uPAR-interactome”, consisting of uPAR ligands, urokinase-type plasminogen activator (uPA) and sushi repeat-containing protein X-linked 2 (SRPX2), as well as plasminogen activator inhibitors (PAI-1, PAI-2) (Eden et al., 2011), uPAR-interactome modulates physiological processes like cellular adhesion, proliferation, differentiation and migration through proteolysis in normal and pathologic processes (Sumi et al., 1992, Preissner et al., 2000, Semina et al., 2016). For example, uPAR has been shown to regulate brain plasticity during development and after brain insults (Lahtinen et al., 2006, Liu et al., 2010, Smith and Marshall, 2010, Archinti et al., 2011, Quirico-Santos et al., 2013). Deficiency in uPAR encoding gene, Plaur, results in abnormal development of cortical and hippocampal inhibitory circuitries in Plaur−/− mice (Powell et al., 2003). Furthermore, Plaur deficiency results in more severe epilepsy phenotype and is associated with a delayed inflammatory response in mice after intrahippocampal kainate injection (Ndode-Ekane and Pitkänen, 2013). Deficiency in uPA results in impaired motor recovery and tissue repair after TBI (Lahtinen et al., 2006, Lahtinen et al., 2009, Bolkvadze et al., 2015). Taken together, uPAR interactome plays an important role in post-injury outcome. However, the underlying molecular interactions are not well characterized.

SRPX2 is a novel ligand of uPAR and has been associated with language development, synaptic plasticity, tissue remodeling and angiogenesis during development (Roll et al., 2006, Roll et al., 2010, Royer-Zemmour et al., 2008, Sia et al., 2013). Similar to uPAR, SRPX2 has been associated with epileptogenic alterations in the brain. For instance, recent studies have associated two pathological mutations in the SRPX2 gene in humans with Rolandic epilepsy, oral and speech dyspraxia, mental retardation, and polymicrogyra (Roll et al., 2006, Roll et al., 2010) [but see (Reinthaler et al., 2014)].Co-immunoprecipitation assays demonstrated interaction between SRPX2 and uPAR, and SRPX2 was shown to interact with extracellular domains (DI-III) of uPAR in vitro (Royer-Zemmour et al., 2008). The SRPX2–uPAR interaction initiates neuronal migration and results in cortical excitability (Salmi et al., 2013). In cancer cells, SRPX2 interacts with uPAR on the cell surface and activates P12k/Akt, Ras/MAPK, and P-FAK/Akt pathways, leading to activation of matrix metalloproteinases (MMP2 and MMP9) (Yamada et al., 2014, Tang et al., 2016, Lin et al., 2017, Liu et al., 2017). Therefore, the interaction of SRPX2 with uPAR and their overlapping physiological functions make SRPX2 a promising target for tissue repair and remodeling after acquired brain injury. However, very little is known about the role of uPAR interactome or acquired factors in the regulation of SRPX2 expression.

We recently showed a phylogenetically conserved expression of SRPX2 protein in the paraventricular, periventricular and supraoptic nuclei of the hypothalamus (Anwer et al., 2018). Impaired hypothalamic function has been reported in humans and experimental models after TBI (Colicos et al., 1996, Taylor et al., 2008, Szmydynger-Chodobska et al., 2011, Osterstock et al., 2014, Tanriverdi et al., 2015). For instance, post-TBI reduction in vasopressin levels in patients results in diabetes insipidus indicating damage to the hypothalamo-hypophyseal axis (Capatina et al., 2015). Controlled cortical impact injury (CCI) model of TBI induces a long-lasting growth hormone (GH) deficiency in mice (Osterstock et al., 2014). Additionally, dystrophic neurons were observed in hypothalamic tissue of rats after CCI-induced TBI (Colicos et al., 1996). However, it is not known whether TBI affects hypothalamic SRPX2 expression.

As a first step to understand the factors that influence SRPX2 expression, we hypothesized that a genetic deficiency in uPAR-interactome and/or TBI-induced secondary hypothalamic damage regulates SRPX2 expression in mice. Therefore, we investigated whether SRPX2 expression is altered by a deficiency of its receptor, uPAR and its other ligand, uPA, and to identify TBI-induced changes in SRPX2 expression in wild type and uPAR or uPA-deficient mice. Our data show that SRPX2 expression in the hypothalamus is resistant to the effects of genetic deficiency or acquired injury, whereas uPAR and uPA expression is regulated by CCI.

Section snippets

Study design

To investigate the effect of uPAR or uPA deficiency (genotype effect) and acquired brain injury (injury effect) on SRPX2 expression, three cohorts of mice were used. The overall study design and animal numbers per group are summarized in Fig. 1.

Genotype and injury effects on SRPX2 expression

In order to understand the contribution of uPAR interactome in the regulation of SRPX2 expression in brain, we investigated the effect of uPAR or uPA deficiency and acquired brain injury on SRPX2 expression using immunohistochemistry (cohort 1 and 2) and RT-qPCR (cohort 3).

Discussion

We tested the hypothesis that SRPX2 expression is regulated by uPAR interactome. We investigated whether a deficiency in uPAR, or its key ligand uPA, affects the expression of SRPX2 in brain and if this expression changes following CCI in mice. We found that (i) genetic deficiency of uPAR and uPA did not affect the total number of SRPX2 immunoreactive neurons or Srpx2 gene expression in the hypothalamus; (ii) CCI-induced TBI did not regulate the expression of SRPX2 protein in the hypothalamus

Acknowledgments

This work was supported by the Academy of Finland (A.P.), European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No. 642881 (ECMED; A.P., M.A.). We thank Mr. Jarmo Hartikainen and Mrs. Merja Lukkari for their excellent technical assistance.

Conflict of interest statement

The authors confirm that there are no conflicts of interest.

Author contributions

M.A., T.B., X.N., N.P., and A.P. Designed the research.

M.A., T.B. Performed the research.

M.A., X.N., N.P., A.P. Analyzed the data.

M.A. and A.P. Wrote the paper with input from all authors.

References (58)

  • T Masos et al.

    mRNAs encoding urokinase-type plasminogen activator and plasminogen activator inhibitor-1 are elevated in the mouse brain following kainate-mediated excitation

    Mol Brain Res

    (1997)
  • A Pitkänen et al.

    Epilepsy related to traumatic brain injury

    Neurotherapeutics

    (2014)
  • A Pitkänen et al.

    Posttraumatic epilepsy — disease or comorbidity?

    Epilepsy Behav

    (2014)
  • A Pitkänen et al.

    Neural ECM and epilepsy

    Prog Brain Res

    (2014)
  • KT Preissner et al.

    Urokinase receptor: a molecular organizer in cellular communication

    Curr Opin Cell Biol

    (2000)
  • T Quirico-Santos et al.

    Increased metalloprotease activity in the epileptogenic lesion—lobectomy reduces metalloprotease activity and urokinase-type uPAR circulating levels

    Brain Res

    (2013)
  • J Rantala et al.

    Urokinase-type plasminogen activator deficiency has little effect on seizure susceptibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice

    Epilepsy Behav

    (2015)
  • E Semina et al.

    Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching

    Eur J Cell Biol

    (2016)
  • S Soleman et al.

    Targeting the neural extracellular matrix in neurological disorders

    Neuroscience

    (2013)
  • K.D. Statler et al.

    Traumatic brain injury during development reduces minimal clonic seizure thresholds at maturity

    Epilepsy Res

    (2008)
  • K.D. Statler et al.

    A potential model of pediatric posttraumatic epilepsy

    Epilepsy Res

    (2009)
  • M Anwer et al.

    Sushi repeat-containing protein X-linked 2: a novel phylogenetically conserved hypothalamo-pituitary protein

    J Comp Neurol

    (2018)
  • M Archinti et al.

    The urokinase receptor in the central nervous system

    CNS Neurol Disord Drug Targets

    (2011)
  • CR Baumann et al.

    Loss of hypocretin (orexin) neurons with traumatic brain injury

    Ann Neurol

    (2009)
  • R Beschorner et al.

    Lesion-associated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans

    Neuropathol Appl Neurobiol

    (2000)
  • T Bolkvadze et al.

    Development of post-traumatic epilepsy after controlled cortical impact and lateral fluid-percussion-induced brain injury in the mouse

    J Neurotrauma

    (2012)
  • N Bruneau et al.

    The role of the urokinase receptor in epilepsy, in disorders of language, cognition, communication and behavior, and in the central nervous system

    Curr Pharm Des

    (2011)
  • C Capatina et al.

    Diabetes insipidus after traumatic brain injury

    J Clin Med

    (2015)
  • MC Dewan et al.

    Estimating the global incidence of traumatic brain injury

    J Neurosurg

    (2018)
  • Cited by (2)

    View full text